🇺🇸 FDA
Patent

US 9199993

8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists

granted A61KA61K31/46A61K31/485

Quick answer

US patent 9199993 (8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists) held by Theravance Biopharma R&D IP, LLC expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance Biopharma R&D IP, LLC
Grant date
Tue Dec 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K31/46, A61K31/485, A61P, A61P1/00